Bellicum Pharmaceuticals


Gelesis is developing a breakthrough therapy (Gelesis100) to fulfill the unmet need for a product that can safely induce significant weight loss. Gelesis100 was developed for overweight and obese individuals, as well as patients with impaired fasting glucose and diabetes who would particularly benefit from weight reduction but for whom weight loss is often a challenge.

Select Venture Capital & Financial Partners

ExoTech Bio Solutions OrbiMed Advisors Orbimed Capital PureTech Ventures Queensland BioCapital